Framework agreement for in-vivo studies using mouse NB-PDX models

Charité – Universitätsmedizin Berlin is procuring a single-supplier framework agreement for in-vivo therapy, characterization or biodistribution/pharmacokinetic studies using patient-derived neuroblastoma xenograft models in mice, including collection of PDX tumour material. The term is 48 months, with a stated maximum of three 12-month renewals. Electronic offers are due 23 October 2026 at 10:00
08:00 AM · UTC
Contract value
Not stated in the notice
Classification
Pre-clinical research services
Published
September 22, 2026

Bekanntmachungsservice - öffentlichevergabe.de

Overview

Charité – Universitätsmedizin Berlin is procuring a single-supplier framework agreement for in-vivo therapy, characterization or biodistribution/pharmacokinetic studies using patient-derived neuroblastoma xenograft models in mice, including collection of PDX tumour material. The term is 48 months, with a stated maximum of three 12-month renewals. Electronic offers are due 23 October 2026 at 10:00 UTC+02:00 (08:00 UTC).

Information based on the public notice

What the buyer needs

Framework agreement for in-vivo studies using mouse NB-PDX models

Tender details

Buyer
Charité - Universitätsmedizin Berlin
Country
Germany
Procedure
open
Classification
Pre-clinical research services · 73111000 · CPV 73110000
Notice reference
ocds-mnwr74-db3d3fea-1cf3-4ba7-92b0-3f833c6e0285
Submission deadline
Charité – Universitätsmedizin Berlin is procuring a single-supplier framework agreement for in-vivo therapy, characterization or biodistribution/pharmacokinetic studies using patient-derived neuroblastoma xenograft models in mice, including collection of PDX tumour material. The term is 48 months, with a stated maximum of three 12-month renewals. Electronic offers are due 23 October 2026 at 10:00

Original notice

Read the original description

Rahmenvertrag über In-Vivo-Studien an NB-PDX-Modellen in Mäusen

Rahmenvertrag über In-Vivo-Studien an NB-PDX-Modellen in Mäusen Die Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin schreibt einen Rahmenvertrag über die Durchführung von In-Vivo-Studien (Therapie, Charakterisierung oder Bioverteilung/Pharmakokinetikstudien) an patientenabgeleiteten Neuroblastom-Xenograft-Modellen in Mäusen ("NB-PDX-Modellen") nebst Entnahme von PDX-Tumormaterial aus. Es handelt sich hierbei um einen Rahmenvertrag mit nur einem Auftragnehmer. Es bestehen gesonderte Anforderungen nach dem Berliner Ausschreibungs- und Vergabegesetz (BerlAVG), siehe Vergabeunterlagen. Nähere Informationen können den auf der Vergabeplattform der Charité (https://vergabeplattform.charite.de) zur Verfügung gestellten Unterlagen entnommen werden. Offer submission deadline: 2026-10-23T10:00:00+02:00

Official source: Bekanntmachungsservice - öffentlichevergabe.de ↗